No Detail Found!

Response to Recombinant Human Growth Hormone (rhGH) Therapy in Children with Growth Hormone De ciency

Author(s)
Maira Riaz Department of Paediatric Endocrinology, National Institute of Child Health,Karachi,Pakistan
Mohsina Noor Ibrahim Department of Paediatric Endocrinology, National Institute of Child Health,Karachi,Pakistan
Versha Rani Rai Department of Paediatric Endocrinology, National Institute of Child Health,Karachi,Pakistan
Safia Bibi NIH-Health Research Institute, Research Centre NICH,Karachi,Pakistan
Zubair Ahmed Khoso Department of Paediatric Endocrinology, National Institute of Child Health,Karachi,Pakistan
Taj Mohammad Laghari Department of Paediatric Endocrinology, National Institute of Child Health,Karachi,Pakistan
Abstract
Objective: To determine the auxological response to recombinant human growth hormone (rhGH) therapy in children with growth hormone de ciency (GHD) presenting at the National Institute of Child Health, Karachi, Pakistan. Study Design: Observational study. Place and Duration of the Study:Department of Paediatric Endocrinology, National Institute of Child Health, Karachi, Pakistan, from January 2022 to December 2023. Methodology: All pre-pubertal children with short stature aged 3-12 years diagnosed with GHD and who were prescribed rhGH therapy were included in the study. Children with any other underlying reason for short stature or any other comorbidity were excluded. Patients demographics and baseline growth parameters were recorded in a pre-designed proforma. Patients were then followed up every three months till one year. Response to rhGH therapy was evaluated through comparison of growth parameters before and after one year of therapy. Results: A total of 90 children including 47 (52.2%) males and 43 (47.8%) females with GHD were enrolled. Mean age of these patients was 7.92 ± 2.647 years. A statistically signi cant change in height (SD), Weight (SD), and BMI (SD) was observed before and after one year of therapy (p <0.001). Response to therapy in terms of height did not di er signi cantly with respect to gender (p = 0.955) or stimulated growth hormone levels (p = 0.911). However, response to rhGH therapy was signi cantly better in terms of increase in height, weight, and BMI in patients presenting earlier i.e. at age d8 years. Conclusion: Recombinant human growth hormone therapy was e ective in children with short stature to achieve desirable growth. Children diagnosed and treated at a younger age d(8years) achieve better height outcomes as compared to those presenting late.
Publication Details
Page(s) 932-935
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 34, Issue: 8, Year: 2024

Request the full text from PASTIC

Keywords
Short stature, Recombinant human growth hormone, Growth hormone de ciency
0

Citations

0

Downloads

52

Views